107 related articles for article (PubMed ID: 26482555)
1. Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients.
Horikawa N; Baba T; Matsumura N; Murakami R; Abiko K; Hamanishi J; Yamaguchi K; Koshiyama M; Yoshioka Y; Konishi I
BMC Cancer; 2015 Oct; 15():739. PubMed ID: 26482555
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer.
Sugiyama T; Nishida T; Hasuo Y; Fujiyoshi K; Yakushiji M
Gynecol Oncol; 1998 May; 69(2):130-6. PubMed ID: 9600820
[TBL] [Abstract][Full Text] [Related]
3. Genetic variations in the PI3K/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in squamous cervical cancer.
Guo L; Wu H; Zhu J; Zhang C; Ma J; Lan J; Xie X
Life Sci; 2015 Dec; 143():217-24. PubMed ID: 26585822
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer--irinotecan and platinum chemotherapy.
Matsumura M; Takeshima N; Ota T; Omatsu K; Sakamoto K; Kawamata Y; Umayahara K; Tanaka H; Akiyama F; Takizawa K
Gynecol Oncol; 2010 Nov; 119(2):212-6. PubMed ID: 20709382
[TBL] [Abstract][Full Text] [Related]
5. Proteomic identification of predictive tissue biomarkers of sensitive to neoadjuvant chemotherapy in squamous cervical cancer.
Guo L; Zhang C; Zhu J; Yang Y; Lan J; Su G; Xie X
Life Sci; 2016 Apr; 151():102-108. PubMed ID: 26947588
[TBL] [Abstract][Full Text] [Related]
6. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of serum squamous cell carcinoma antigen in patients with cervical cancer who receive neoadjuvant chemotherapy followed by radical surgery: a single-institute study.
Li X; Zhou J; Huang K; Tang F; Zhou H; Wang S; Jia Y; Sun H; Ma D; Li S
PLoS One; 2015; 10(4):e0122361. PubMed ID: 25860888
[TBL] [Abstract][Full Text] [Related]
8. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.
Kim K; Kang SB; Chung HH; Kim JW; Park NH; Song YS
Gynecol Oncol; 2008 Dec; 111(3):509-15. PubMed ID: 18851872
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.
Chen H; Liang C; Zhang L; Huang S; Wu X
Gynecol Oncol; 2008 Sep; 110(3):308-15. PubMed ID: 18606439
[TBL] [Abstract][Full Text] [Related]
10. Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer.
Scambia G; Benedetti Panici P; Foti E; Amoroso M; Salerno G; Ferrandina G; Battaglia F; Greggi S; De Gaetano A; Puglia G
J Clin Oncol; 1994 Nov; 12(11):2309-16. PubMed ID: 7964945
[TBL] [Abstract][Full Text] [Related]
11. Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy.
Lee JY; Kim YH; Kim MJ; Kim K; Chung HH; Park NH; Song YS; Kang SB
Arch Gynecol Obstet; 2011 Aug; 284(2):477-82. PubMed ID: 20878172
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant docetaxel combined with cisplatin and followed by radical surgery for the treatment of locally advanced (stage IB2 - IIB) cervical cancer: preliminary results of a single-institution experience.
Huang X; Lan C; Huang H; Zhang Y; Huang H; Cao X; Huang Y; Guo Y; Wan T; Liu J
Expert Opin Pharmacother; 2011 Feb; 12(2):165-73. PubMed ID: 21226631
[TBL] [Abstract][Full Text] [Related]
13. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer.
Chung HH; Kim MK; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Gynecol Oncol; 2006 Dec; 103(3):1031-7. PubMed ID: 16875718
[TBL] [Abstract][Full Text] [Related]
14. [Comparative analysis of neoadjuvant therapies in stage Ib2 and IIa2 cervical carcinoma].
Hu JL; Wu LY; Li N; Li XG; Huang MN; Zhang R
Zhonghua Fu Chan Ke Za Zhi; 2012 Jun; 47(6):452-7. PubMed ID: 22932113
[TBL] [Abstract][Full Text] [Related]
15. CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma.
Costa S; Terzano P; Bovicelli A; Martoni A; Angelelli B; Santini D; Ceccarelli C; Lipponen P; Erzén M; Syrjänen S; Syrjänen K
Gynecol Oncol; 2001 Jan; 80(1):67-73. PubMed ID: 11136572
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer.
Angioli R; Plotti F; Montera R; Aloisi A; Luvero D; Capriglione S; Terranova C; De Cicco Nardone C; Muzii L; Benedetti-Panici P
Gynecol Oncol; 2012 Nov; 127(2):290-6. PubMed ID: 22819938
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: has this regimen still a role as neoadjuvant setting?
Moioli M; Papadia A; Mammoliti S; Pacella E; Menoni S; Menada MV; Ragni N
Minerva Ginecol; 2012 Apr; 64(2):95-107. PubMed ID: 22481620
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study.
Takano M; Kato M; Yoshikawa T; Sasaki N; Hirata J; Furuya K; Takahashi M; Yokota H; Kino N; Horie K; Goto T; Fujiwara K; Ishii K; Kikuchi Y; Kita T
Oncology; 2009; 76(5):315-21. PubMed ID: 19299905
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
